Quoin Pharmaceuticals (QNRX) Expected to Announce Quarterly Earnings on Monday

Quoin Pharmaceuticals (NASDAQ:QNRX) is anticipated to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.99) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 9:30 AM ET.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings data on Friday, March 27th. The company reported ($14.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.42) by ($8.38).

Quoin Pharmaceuticals Stock Performance

Shares of NASDAQ QNRX traded up $0.08 during mid-day trading on Monday, hitting $6.29. The stock had a trading volume of 3,447 shares, compared to its average volume of 81,466. Quoin Pharmaceuticals has a 1 year low of $5.20 and a 1 year high of $41.80. The business has a 50 day moving average price of $7.27 and a two-hundred day moving average price of $10.73. The firm has a market cap of $11.31 million, a P/E ratio of -0.18 and a beta of 1.61.

Institutional Trading of Quoin Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of QNRX. Ikarian Capital LLC purchased a new stake in shares of Quoin Pharmaceuticals in the 4th quarter worth about $3,052,000. Millennium Management LLC purchased a new stake in Quoin Pharmaceuticals during the 4th quarter valued at about $1,080,000. SummitTX Capital L.P. bought a new position in Quoin Pharmaceuticals during the 4th quarter valued at about $935,000. Boothbay Fund Management LLC bought a new position in Quoin Pharmaceuticals during the 4th quarter valued at about $863,000. Finally, ADAR1 Capital Management LLC bought a new position in Quoin Pharmaceuticals during the 4th quarter valued at about $840,000. 8.63% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Quoin Pharmaceuticals has a consensus rating of “Sell”.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.